Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TEVIMBRA Beigene Aus Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Apr-2024
Active ingredients
tislelizumab
Proposed indication
Indicated for the first-line treatment of locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Application type
A (new medicine)
Publication date
Apr-2024